Nama Insights

Protagonist Therapeutics (PTGX)

Healthcare · Biotechnology · NASDAQ

Protagonist Therapeutics (PTGX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $8.09B, a trailing price-to-earnings ratio of 26.3 and a free-cash-flow yield of 0.7%. Over the most recent reported fiscal year, revenue declined 89.4% and free cash flow per share fell 68.6%. Nama's AI scorecard rates it Buy, 6.0 out of 10. On 12-month momentum it ranks in the leading band of its market.
AI scorecard
Buy · 6.0/10
Positive, at the low end of Buy. As of Nov 20, 2026.
Momentum
Leading · +64.0% over 12 months ex. last
Top 20% of its market on the past year's steady rise.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-24.5%
How far the last close sits under the highest price of the past five years.
Market cap$8.09B
Trailing P/E26.3
Price / book7.5
Price / sales14.7
FCF yield0.7%
Dividend yield—
Gross margin99.8%
Operating margin58.6%
Net margin62.0%
Revenue growth (YoY)-89.4%
Revenue growth (3-yr annual)+20.1%
EPS growth (YoY)-148.8%
FCF/share growth (YoY)-68.6%
Beta1.2
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology

PTGX earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$0.22). Beat the EPS estimate in 3 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 5, 2026 $3.07 $2.66 +15.4% $274.41M
Q2 2026 Aug 5, 2026 $2.29 $1.94 +18.0% $213.47M
Q1 2026 May 5, 2026 $0.05 -$0.65 +107.7% $56.37M
Q4 2025 Feb 25, 2026 -$0.69 -$0.54 -27.8% $7.44M

PTGX analyst price target

Median target $181.00 from 14 analysts, ranging $151.00 – $225.00.

Biotechnology peers

TickerCompanyMarket capP/E
VRTX Vertex Pharmaceuticals $132.01B 27.4
REGN Regeneron Pharmaceuticals $95.52B 16.7
MRNA Moderna $80.65B —
ARGX argenx $59.24B 32.9
ONC BeOne Medicines $45.66B 50.8
RPRX Royalty Pharma $38.94B 12.8
RVMD Revolution Medicines $34.48B —
INSM Insmed $31.69B —
Explore live PTGX data on Nama Insights →

PTGX FAQ

Is PTGX a buy?
Nama's AI scorecard currently rates Protagonist Therapeutics Buy (6.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is PTGX's P/E ratio?
Protagonist Therapeutics trades at a trailing price-to-earnings ratio of 26.3.
When does PTGX report earnings?
Protagonist Therapeutics's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.22.
What is the PTGX price target?
The median analyst price target from 14 analysts is $181.00, with a range of $151.00 – $225.00.
Is PTGX Shariah compliant?
Nama's AAOIFI-style screen reads Protagonist Therapeutics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.